Too early to say if cloud over pharma stocks has fully lifted, says BMO's Seigerman

Healthcare the second worst performer this year with pharma names under pressure. Those valuations also nearing 15-year lows. And that combined with increased clarity on the Trump administration's drug pricing efforts has us wondering whether the sector now offers investors value or if it's still a value trap.Joining us now to discuss is Beimo Capital Markets, Evan David Seagerman. Evan, great to have you with us. >> Thank you for having me.It feels like what we learned from the Fiser announcement yesterday ...